ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "infection and rheumatoid arthritis (RA)"

  • Abstract Number: 1505 • 2016 ACR/ARHP Annual Meeting

    Trends in Hospitalizations for Infections in US Patients with Rheumatoid Arthritis, 1993-2013

    Sadao Jinno1, Na Lu2,3, S. Reza Jafarzadeh4 and Maureen Dubreuil3,5, 1Rheumatology, Boston University School of Medicine, Boston, MA, 2Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 3Clinical Epidemiology, Boston University School of Medicine, Boston, MA, 4Medicine, Washington University School of Medicine, St Louis, MO, 5Rheumatology, Boston VA HealthCare System, Boston, MA

    Background/Purpose: With the increasing uptake of RA treatments that confer infection risk, an increase in the rates of infection hospitalizations among RA patients is expected,…
  • Abstract Number: 2001 • 2016 ACR/ARHP Annual Meeting

    Perioperative Use of Synthetic Disease-Modifying Anti-Rheumatic Drugs or Tumor Necrosis Factor α Inhibitors Does Not Associate with Increased Rates of Post-Operative Infections

    Hsin-Hsuan Juo1,2, Anders Peck3,4, Nancy Gove5 and Bernard Ng1,2, 1Division of Rheumatology, Department of Medicine, University of Washington, Seattle, WA, 2Rheumatology, VA Puget Sound Healthcare System, Seattle, WA, 3Medicine / Rheumatology, University of Washington, Seattle, WA, 4The Seattle Arthritis Clinic, Seattle, WA, 5Biostatistics, Seattle Children's Research Institute, Seattle, WA

    Background/Purpose: The aim of the study is to assess whether the risk of post-operative infectious complications in rheumatoid arthritis (RA) patients undergoing surgical procedures is…
  • Abstract Number: 2053 • 2016 ACR/ARHP Annual Meeting

    Prosthetic Joint Infection with Staphylococcus Aureus: Recurrence after Surgical Treatment in U.S. Veterans with and without Rheumatoid Arthritis

    Namrata Singh1, Rajeshwari Nair2, Michihiko Goto3, Elizabeth Field4,5, Petar Lenert6, Ryan Carnahan7, Marin Schweizer2 and Eli Perencevich2, 1Internal Medicine, University of Iowa Hospitals and Clinics and Iowa City VA, Iowa City, IA, 2Internal Medicine, Iowa City VA, Iowa City, IA, 3Iowa city VA and UIHC, Iowa City, IA, 410e-01 Building 1 Vamc, University of Iowa, Iowa City, IA, 5Iowa City VA, Iowa City, IA, 6333 MRC Dept of Internal Med, University of Iowa, Iowa City, IA, 7Epidemiology, College of public health, UI, Iowa City, IA

    Background/Purpose:  Studies have shown rheumatoid arthritis (RA) to be a risk factor for development of prosthetic joint infections (PJI) and for worse outcome from PJI…
  • Abstract Number: 120 • 2016 ACR/ARHP Annual Meeting

    Reproductive Tract Infections (RTI) in Indian (Asian) Women of Child Bearing Age Suffering from RA:I Don’t Ask Them, They Don’t Tell Me

    Anuradha Venugopalan1, Jaleh Naderi2, Renu Relwani3 and Arvind Chopra4, 1Rheumatology, Microbiologist, Pune, India, 2Rheumatology, PhD Student, Urrmia, Iran, 3Rheumatology, Gynaecologist, Pune, India, 4Center for Rheumatic Diseases, Director and Chief Rheumatologist, Pune, India

    Background/Purpose: Several factors including disease process and drug therapy allegedly predispose to infections in RA. Socioeconomic constraints on our setting impose unique impediments. RTI are…
  • Abstract Number: 35 • 2015 ACR/ARHP Annual Meeting

    Rheumatoid Arthritis As a Risk Factor for Cardiovascular Events Following Hospitalized Pneumonia; A Population-Based Cohort Study

    Mette Holland-Fischer1, Ulrik Tarp2, Reimar W. Thomsen3 and Mette Nørgaard3, 1Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark, 2Department of Rheumatology, Aarhus University Hospital, AArhus, Denmark, 3Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark

     Background/Purpose: Cardiovascular disease is a major cause of morbidity and mortality in patients with Rheumatoid Arthritis (RA). Patients with RA do also have an increased…
  • Abstract Number: 561 • 2015 ACR/ARHP Annual Meeting

    Improvement in Disease Activity and the Long-Term Risk of Serious Infectious Events in Rheumatoid Arthritis Patients Treated with Certolizumab Pegol

    Jeffrey R. Curtis1, Marc de Longueville2, Cathy O'Brien2 and Boulos Haraoui3, 1University of Alabama at Birmingham, Birmingham, AL, 2UCB Pharma, Brussels, Belgium, 3Department of Medicine, Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada

    Background/Purpose: Anti-TNF drugs are an effective treatment option for rheumatoid arthritis (RA) patients (pts) but have been associated with an increased incidence of serious infectious…
  • Abstract Number: 610 • 2015 ACR/ARHP Annual Meeting

    Risk of Herpes Zoster in Patients with Rheumatoid Arthritis Treated with Biologic Disease-Modifying Therapy Compared with Conventional Therapy

    Hyun Mi Kwon, Sang Jin Lee, Ji Ae Yang, Jin Young Moon, Eun Young Ahn, Jin Kyun Park, Eun Young Lee, Yeong Wook Song and Eun Bong Lee, Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea

    Background/Purpose: Patients with rheumatoid arthritis (RA) are at increased risk for herpes zoster (HZ) infection. RA treatment including immunosuppressant medications could further exacerbate the risk.…
  • Abstract Number: 1531 • 2015 ACR/ARHP Annual Meeting

    The Changing Face of Septic Arthritis Complicating Rheumatoid Arthritis in the Era of Biotherapies. Retrospective Single-Center Study over 35 Years

    Jean-Jacques Dubost1, Bruno Pereira2, Anne Tournadre3, Zuzana Tatar1, Marion Couderc1 and Martin Soubrier1, 1Rheumatology department CHU Clermont-Ferrand, Clermont-Ferrand, France, 2Biostatistics unit (DRCI), CHU Clermont-Ferrand, Clermont-Ferrand, France, 3Rheumatology, UNH-UMR 1019 INRA University of Auvergne and Rheumatology department CHU Clermont-Ferrand, Clermont-Ferrand, France

    Background/Purpose: Rheumatoid arthritis (RA) is a risk factor for septic arthritis (SA), and anti-TNF therapy doubles the risk of SA. The purpose of this study…
  • Abstract Number: 1567 • 2015 ACR/ARHP Annual Meeting

    Occurrence of Serious Infection in Patients with Rheumatoid Arthritis Treated with Biologics and Denosumab Observed in a Clinical Setting

    Matthew Wong-Pack1, Rod Rodjanapiches1, Arthur Lau1,2,3, George Ioannidis1,3, Sally Wade4, Leslie Spangler4, Celia JF Lin4, Patrick Roy-Gayos1, William G Bensen1,3, Robert Bensen3 and Jonathan D Adachi1,3, 1McMaster University, Hamilton, ON, Canada, 2Division of Rheumatology, McMaster University, Hamilton, ON, Canada, 3St Joseph's Healthcare Hamilton, Hamilton, ON, Canada, 4Amgen Inc., Thousand Oaks, CA

    Background/Purpose: Previous studies combining immunosuppressive biologics have shown an increased risk of infections. Few studies have examined the risk of infection with concurrent use of…
  • Abstract Number: 1995 • 2015 ACR/ARHP Annual Meeting

    Does the Risk of Serious Infections Among Elderly RA Patients Differ By Age of Disease Onset?

    Sofia Pedro1, Ted R. Mikuls2 and Kaleb Michaud3, 1National Data Bank for Rheumatic Diseases, Wichita, KS, 2University of Nebraska Medical Center, Omaha, NE, 3Internal Medicine, University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: Elderly-onset RA (EORA) patients (age of onset>60) are less likely to be treated with biologics even when accounting for disease activity compared to young-onset…
  • Abstract Number: 2809 • 2014 ACR/ARHP Annual Meeting

    Human Papilloma Virus and Chlamydia Trachomatis Infections in Rheumatoid Arthitis Under Anti-TNF Therapy

    Mariana G Waisberg1, Ana C.M. Ribeiro2, Wellington M. Candido1, Poliana B. Medeiros1, Cezar N. Matsuzaki3, Mariana C. Beldi1, Maricy Tacla1, Helio H. Caiaffa-Filho4, Eloisa Bonfá1 and Clovis A Silva5, 1Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil, 2Rheumatology Division, University of Sao Paulo, Sao Paulo, Brazil, 3Gynecology Department, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil, 4Central Laboratory Division, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil, 5Pediatric Rheumatology Unit, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil

    Background/Purpose: Cervical human papillomavirus (HPV) infection has been observed in 28% of rheumatoid arthritis (RA) patients in a cross-sectional study with no available data regarding…
  • Abstract Number: 2375 • 2014 ACR/ARHP Annual Meeting

    Should Physician Reduce patients’ Glucocorticoids to Offset the Risk of Serious Infection Event Among RA Patients Who Switched from Non-Biologic Dmards and Glucocorticoid to Biologics?

    Huifeng Yun1, Lang Chen2, George W. Reed3, Joel M. Kremer4, Jeffrey D. Greenberg5 and Jeffrey R. Curtis6, 1Epidemiology, University of Alabama at Birmingham School of Public Health, Birmingham, AL, 2Medicine, University of Alabama at Birmingham, Birmingham, AL, 3Corrona, LLC., Southborough, MA, 4Medicine, Albany Medical College and the Center for Rheumatology, Albany, NY, 5Rheumatology, New York University School of Medicine, New York, NY, 6University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose:  Glucocorticoids (GCs) and biologic disease-modifying antirheumatic drugs (DMARDs) have previously been associated with serious infection events (SIEs) among rheumatoid arthritis (RA) patients. For patients…
  • Abstract Number: 2151 • 2014 ACR/ARHP Annual Meeting

    Abatacept Related Infections: No Association with Gammaglobulin Reduction

    Valquiria Dinis1, Vilma S. T. Viana1, Elaine P. Leon1, Clovis A Silva2, Carla G.S. Saad3, Julio C. B. Moraes3, Eloisa Bonfá3 and Ana C.M. Ribeiro4, 1Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, 2Pediatric Rheumatology Unit, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, 3Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, 4Division of Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil

    Background/Purpose A recent study reported that abatacept (ABA) reduces rheumatoid arthritis  (RA) related autoantibodies and gammaglobulins levels. However, the possible association of these findings with…
  • Abstract Number: 820 • 2014 ACR/ARHP Annual Meeting

    Herpes Zoster Infection Risk in Auto-Immune and Inflammatory Diseases: Implications for Vaccination

    Huifeng Yun1, Shuo Yang2, Lang Chen3, Fenglong Xie4, Kevin L. Winthrop5, John Baddley3, Kenneth G. Saag6, Jasvinder A. Singh7 and Jeffrey R. Curtis8, 1Epidemiology, University of Alabama at Birmingham School of Public Health, Birmingham, AL, 2Clinical Immunology/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 3Medicine, University of Alabama at Birmingham, Birmingham, AL, 4Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, 5Division of Infectious Diseases, Oregon Health and Science University, Portland, OR, 6Immunology & Rheumatology, The University of Alabama at Birmingham, Birmingham, AL, 7University of Alabama at Birmingham, Birmingham, AL, 8Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Herpes zoster (HZ) vaccine is recommended for healthy people age >= 60 years in US. It is unclear whether the absolute risk for younger…
  • Abstract Number: 478 • 2014 ACR/ARHP Annual Meeting

    Adverse Events and Infections in Patients with Rheumatoid Arthritis Treated with Conventional Drugs or Biologic Agents: A Real World Study

    Christos E. Lampropoulos1, Philippos Orfanos2, Vasiliki-Kalliopi Bournia3, Theofilos P. Karatsourakis4, Clio P. Mavragani5, Dimitrios Pikazis4, Menelaos N. Manoussakis6, Athanasios G. Tzioufas4, Haralampos M. Moutsopoulos7 and Panayiotis G. Vlachoyiannopoulos3, 1Department of Pathophysiology, School of Medicine, National University of Athens, Athens, Greece, 2Department of Hygiene, Epidemiology and Medical Statistics, Medical School, National University of Athens, Athens, Greece, 3First Department of Propedeutic Internal Medicine, Laikon Hospital, Athens University Medical School, Athens, Greece, 4Pathophysiology, School of Medicine, National University of Athens, Athens, Greece, 5Department of Experimental Physiology, School of Medicine, University of Athens, Athens, Greece, Athens, Greece, 6Pathophysiology, School of Medicine, National University of Athens, Greece, Athens, Greece, 7Department of Pathophysiology, School of Medicine, University of Athens, Athens, Greece

    Background/Purpose: Rheumatoid arthritis (RA) is a chronic, inflammatory disease with joint destruction and permanent disability. Biologic agents (BAs) offer a better outcome when disease is…
  • « Previous Page
  • 1
  • 2
  • 3
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology